Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Guardant Health, Inc. (GH)

Guardant Health adds Kevin Sayer to board and names Robert Parks chief accounting officer

Neutral Impact 2 of 5 leadership Written later

Guardant Health increased its board to 11 seats and appointed Kevin R. Sayer, former Dexcom CEO, as a Class II director effective November 2, 2026. The company also named Robert A. Parks as Chief Accounting Officer and principal accounting officer on the same date, replacing no named predecessor in the filing. The changes add board and finance leadership but the filing discloses no financial results.

Key points

  • Kevin R. Sayer, 68, appointed Class II director effective November 2, 2026, with a term expiring at the 2029 Annual Meeting
  • Sayer to receive a restricted stock unit award valued at $500,000 and a $60,000 annual cash retainer
  • Robert A. Parks, 54, appointed Chief Accounting Officer and principal accounting officer; previously CAO of Fortrea Holdings Inc. from August 2024 to August 2026

The filing

CompanyGuardant Health, Inc. (GH)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:40 PM ET
Accession number0001193125-26-445514

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.